NIH Ends Gene Therapy Trial Reporting Requirements In Reg Streamlining Move
Executive Summary
Trial protocols, annual reports, and adverse event reports on gene therapies will only go to US FDA under now-finalized amendments, a sign that the product category is maturing and can be regulated like other drugs and biologics.